Blood Thinning

Both warfarin and DOACs exert a significant independent protective effect on all-cause mortality, reinforcing the centrality of anticoagulation adherence in high-risk AF patients. Both warfarin and DOACs were independently associated with reduced all-cause mortality in multimorbid AF patients. Anticoagulation therapy reduces the risk of thromboembolism in atrial fibrillation. Early AF management in high-comorbidity patients consistently reduces cardiovascular events, stroke, and all-cause death. Warfarin use in non-valvular AF was significantly higher in the multimorbidity group than in the oligomorbidity group (31.4% versus 23.7%). NOACs are currently preferred over vitamin K antagonists for AF management due to superior safety profiles, ease of administration, and comparable or better efficacy. The standard treatment duration for blood clots is three months of anticoagulation therapy. When D-dimer thresholds are met, full-dose anticoagulation is initiated with either low-molecular-weight heparin or intravenous unfractionated heparin. D-dimer is the most commonly used marker for clot burden in COVID-19 but is an imperfect, indirect measure. The protective effect of anticoagulatio…